A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors

Completed · Phase 1

Conditions studied: Epithelial Tumors, Malignant

In brief

This is a Phase I, multicenter, open-label study of MEHD7945A in participants with incurable, locally advanced, or metastatic epithelial malignancies that have progressed despite standard therapy or for which no standard therapy exists. The study will be conducted in two stages: a dose escalation stage and an expansion stage. The dose-escalation stage is designed to evaluate the safety, tolerability, and PK of MEHD7945A administered (at five dose levels from 1 to 30 milligrams per kilogram \[mg/kg\]) every 2 week (Q2W). An expansion stage will be initiated after establishment of maximum tolerated dose (MTD) in dose escalation stage. Participants with refractory or recurrent metastatic colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and pancreatic cancer will be enrolled in an expansion stage to better characterize the safety, tolerability, PK and preliminary assessment of the anti-tumor activity of MEHD7945A.

Key facts

Study ID

NCT01207323

Run by

Genentech, Inc.

People needed

66

Starts

2010-11-09

Expected to finish

2018-04-23

Last updated by the study team

2018-05-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Life expectancy greater than or equal to (>/=) 12 weeks
• Availability and willingness to provide sufficient tumor tissue sample for testing
• Dose-escalation stage: Participants with histologically documented incurable, locally advanced, or metastatic epithelial malignancy that has progressed despite standard therapy or for which no standard therapy exists
• Expansion stage: Participants with one of the following epithelial, histologically-documented, incurable, locally advanced, or metastatic tumor that has progressed despite standard therapy or for which no standard therapy exists: CRC, NSCLC, HNSCC, or pancreatic cancer
• Use of an effective means of contraception (e.g., abstinence, hormonal or double barrier method, surgically sterilized partner) for men and women of childbearing potential while enrolled in the study

You may not qualify if…

• Less than (<) 4 weeks since the last anti-tumor therapy prior to Day 1 of study treatment
• Major surgical procedure within 4 weeks prior to Cycle 1, Day 1
• Leptomeningeal disease as the only manifestation of the current malignancy
• Active infection requiring IV antibiotics
• Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs
• Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy
• Current severe, uncontrolled systemic disease
• History of cardiac heart failure of any New York Heart Association criteria or serious cardiac arrhythmia requiring treatment
• History of myocardial infarction within 6 months before Cycle 1, Day 1, or history of unstable angina
• Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
• History of interstitial lung disease
• History of severe allergic or hypersensitivity reaction to other therapeutic antibodies that required discontinuation of therapy
• Known human immunodeficiency virus (HIV) infection
• Primary central nervous system (CNS) malignancy or untreated/active CNS metastases
• Significant traumatic injury within 4 weeks before Cycle 1, Day 1
• Pregnancy or lactation

Where it is running

• Uni of Colorado Cancer Center; Anschutz Cancer Pavilion — Aurora, Colorado, United States
• Massachusetts General Hospital. — Boston, Massachusetts, United States
• University of Texas M.D. Anderson Cancer Center — Houston, Texas, United States
• Hospital Univ Vall d'Hebron; Servicio de Oncologia — Barcelona, Spain
• HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia — Madrid, Spain
• Hospital Clinico Universitario de Valencia — Valencia, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.